Patrick F. Belcastro, PhD is a Pharmtech editorial advisory board (EAB) member.
Patrick F. Belcastro, PhD
Professor Emeritus,
School of Pharmacy,
Purdue University
Patrick F. Belcastro is professor emeritus of pharmaceutics in the department of industrial and physical pharmacy at Purdue University. He received an MS and PhD degree from Purdue University’s School of Pharmacy and Pharmaceutical Sciences.
His published articles, appearing in various professional and scientific periodicals, cover a wide variety of subject areas, including studies on the effects of x-radiation on the intestinal absorption and thyroid uptake of radioactive iodine-131, the effect of ultrasonic energy on the particle size of suspended pharmaceuticals, and other areas. Belcastro has served as a member of the editorial advisory board of Pharmaceutical Technology since 1977. He is a member of the American Pharmaceutical Association and the American Institute of the History of Pharmacy.
Over the years, Belcastro has taught a wide variety of graduate and undergraduate courses including those involving the manufacture and compounding of parenteral solutions. He has directed graduate studies of doctoral students at Purdue University, where he currently teaches an elective undergraduate course. He has also served as a member of the faculty at Duquesne University and at Ohio State University.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.